AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting
MWN-AI** Summary
AEON Biopharma, Inc. has announced that its abstract featuring data on its lead product, ABP-450 (prabotulinumtoxinA), has been accepted for presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting. This prestigious event will take place from April 18-22, 2026, in Chicago, Illinois, and attracts neurologists who administer a significant volume of therapeutic botulinum toxin treatments.
The abstract, titled "Establishing Primary Structure Comparability Between ABP-450 and OnabotulinumtoxinA (BOTOX®)," focuses on analytical data showing nearly identical primary amino acid sequences between ABP-450 and the reference product, with 93.5% to 99.3% peptide sequence coverage and no observed variant peptides across multiple production lots. This confirmation of primary structure is crucial for establishing the biosimilarity needed for ABP-450’s acceptance under the FDA’s rigorous 351(k) biosimilar pathway, which requires evidence that a proposed biosimilar product has no clinically significant differences in safety and efficacy from its reference counterpart.
Dr. Chad K. Oh, AEON's Chief Medical Officer, will present these findings as a poster during the session dedicated to General Neurology: Pharmaceuticals. The event emphasizes AEON Biopharma's strategic push to penetrate the lucrative U.S. therapeutic neurotoxin market, valued at over $3 billion annually, with the intention of providing a high-quality biosimilar alternative to BOTOX®.
ABP-450 is already approved as a biosimilar in several countries, including India and Mexico, and AEON holds exclusive rights for its therapeutic development in major markets such as the United States and the European Union. The successful establishment of biosimilarity for ABP-450 holds the potential to significantly disrupt the existing market dynamics dominated by BOTOX®.
MWN-AI** Analysis
AEON Biopharma, Inc. (NYSE American: AEON) stands at a critical juncture with the upcoming presentation of its ABP-450 (prabotulinumtoxinA) at the 2026 American Academy of Neurology (AAN) Annual Meeting. This event, set to occur from April 18-22 in Chicago, will spotlight AEON’s efforts to establish analytical similarity to the well-known BOTOX® (onabotulinumtoxinA), which commands a substantial share of the therapeutic neurotoxin market valued at over $3 billion in the U.S.
The company’s demonstration of a nearly identical primary amino acid sequence between ABP-450 and BOTOX® reinforces the potential for regulatory success. The FDA's 351(k) biosimilar pathway emphasizes the necessity for rigorous analytical evidence, which AEON has pursued through its comprehensive data package. With no observed variant peptides across multiple lots, AEON strengthens its case for the product's biosimilarity, a critical element for gaining full-label market access.
As AEON prepares to present its findings, investors should recognize the potential implications on the stock price post-presentation. Should the data be well-received, this could catalyze greater confidence among stakeholders and attract interest from institutional investors. The success of ABP-450 not only comes from potential market share capture from BOTOX® but also from the broader biosimilar segment, which offers a significant opportunity for revenue generation in the coming years.
However, the regulatory landscape remains uncertain, and investors should be aware of the inherent risks outlined in AEON's forward-looking statements. Factors such as market competition, approval timelines, and efficacy results will influence the stock trajectory.
In conclusion, while AEON's position is promising, a cautious approach that weighs both the potential upside and regulatory risks would serve investors well as they contemplate exposure to this biopharmaceutical company on the brink of pivotal developments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced a poster presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026, in Chicago, IL.
The abstract builds upon analytical data previously reported by the Company demonstrating identical primary amino acid sequence between ABP-450 and the reference product, based on 93.5%–99.3% peptide sequence coverage across BoNT/A1 and associated accessory proteins, with no variant peptides observed across multiple lots. Primary structure confirmation represents a foundational component of biosimilar development and supports AEON’s analytical similarity package for ABP-450.
The AAN Annual Meeting represents the largest annual gathering of neurologists in the United States, the specialty responsible for the largest volume of therapeutic botulinum toxin injections.
AAN 2026 Presentation Details:
Title: Establishing Primary Structure Comparability Between ABP-450 (prabotulinumtoxinA) and OnabotulinumtoxinA (Botox®) to Support Biosimilarity
Format: Poster Presentation (abstract # 4146, presentation #010 in Neighborhood 7)
Session: P11: General Neurology: Pharmaceuticals
Presenter: Chad K. Oh, M.D., Chief Medical Officer, AEON Biopharma
Date: Wednesday, April 22, 2026
Time: 11:45 am – 12:45 pm CT
About the U.S. Biosimilar Pathway
Under the FDA’s 351(k) biosimilar pathway, developers must demonstrate that a proposed product is highly similar to an approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. Analytical similarity represents the scientific foundation of this process, integrated with clinical and regulatory strategy to form a totality-of-evidence assessment. FDA engagement focuses on determining the scope of data necessary to address residual uncertainty, which may include analytical, nonclinical, or clinical components as appropriate.
About AEON Biopharma
AEON Biopharma is a biopharmaceutical company seeking accelerated and full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX®. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually and represents a significant opportunity for high-quality biosimilar competition. The Company’s lead asset is ABP-450 for debilitating medical conditions. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau®. ABP-450 is manufactured by Daewoong Pharmaceutical in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency. The product is approved as a biosimilar in India, Mexico, and the Philippines. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or AEON’s future financial or operating performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, regulatory developments, biosimilar program results, and other risks described in the Company’s filings with the Securities and Exchange Commission.
Contacts
Investor Contact:
Laurence Watts
New Street Investor Relations
+1 619 916 7620
laurence@newstreetir.com
FAQ**
What specific milestones does AEON Biopharma Inc. Class A AEON anticipate achieving before the upcoming AAN Annual Meeting in April 2026 regarding ABP-450's clinical development and regulatory status?
How does AEON Biopharma Inc. Class A AEON plan to differentiate ABP-450 from existing competitors in the U.S. therapeutic neurotoxin market, particularly regarding market adoption and physician acceptance?
What data or evidence will AEON Biopharma Inc. Class A AEON present at the AAN Annual Meeting to further assure stakeholders of ABP-450's biosimilarity to BOTOX® in terms of safety and efficacy?
Considering the significance of the U.S. therapeutic neurotoxin market exceeding $3 billion, what are the projected financial impacts for AEON Biopharma Inc. Class A AEON upon successful market entry of ABP-450?
**MWN-AI FAQ is based on asking OpenAI questions about AEON Biopharma Inc. Class A (NYSE: AEON).
NASDAQ: AEON
AEON Trading
10.2% G/L:
$1.2122 Last:
41,588 Volume:
$1.15 Open:
